BioCentury | Jun 16, 2014
Clinical News

Relistor methylnaltrexone regulatory update

...approved with a REMS to treat postoperative ileus. Cubist gained Entereg through its acquisition of Adolor Corp....
BioCentury | Jun 16, 2014
Clinical News

Entereg alvimopan regulatory update

...approved with a REMS to treat postoperative ileus. Cubist gained Entereg through its acquisition of Adolor Corp....
BioCentury | Oct 28, 2013
Clinical News

Entereg alvimopan regulatory update

...anastomosis in patients requiring surgery for colorectal disease. Cubist gained Entereg through its acquisition of Adolor Corp....
BioCentury | Jul 22, 2013
Clinical News

Bevenopran: Phase III started

...see BioCentury, Nov. 5, 2012). Cubist gained the compound through its December 2011 acquisition of Adolor Corp....
BioCentury | Jan 28, 2013
Finance

Oleg's asymmetry

...postoperative ileus (POI) were $11M. Cubist gained the product through its December 2011 acquisition of Adolor Corp....
BioCentury | Jan 7, 2013
Clinical News

Entereg alvimopan regulatory update

...anastomosis in patients requiring surgery for colorectal disease. Cubist gained Entereg through its acquisition of Adolor Corp....
BioCentury | Nov 5, 2012
Clinical News

CB-5945: Phase III started

...slated to begin next half. Cubist gained the compound through its December 2011 acquisition of Adolor Corp....
BioCentury | Oct 22, 2012
Finance

Abbott's wild ride

...drug Entereg alvimopan were $10.1M. Cubist gained the product through its December 2011 acquisition of Adolor Corp....
BioCentury | Sep 5, 2012
Company News

Kalidex debuts

...Michael Dougherty, who joined Kalidex in May, was previously president and CEO at pain company Adolor Corp....
BioCentury | Jul 23, 2012
Finance

In like a lion . . .

...drug Entereg alvimopan were $9.7M. Cubist gained the product through its December 2011 acquisition of Adolor Corp....
Items per page:
1 - 10 of 436
BioCentury | Jun 16, 2014
Clinical News

Relistor methylnaltrexone regulatory update

...approved with a REMS to treat postoperative ileus. Cubist gained Entereg through its acquisition of Adolor Corp....
BioCentury | Jun 16, 2014
Clinical News

Entereg alvimopan regulatory update

...approved with a REMS to treat postoperative ileus. Cubist gained Entereg through its acquisition of Adolor Corp....
BioCentury | Oct 28, 2013
Clinical News

Entereg alvimopan regulatory update

...anastomosis in patients requiring surgery for colorectal disease. Cubist gained Entereg through its acquisition of Adolor Corp....
BioCentury | Jul 22, 2013
Clinical News

Bevenopran: Phase III started

...see BioCentury, Nov. 5, 2012). Cubist gained the compound through its December 2011 acquisition of Adolor Corp....
BioCentury | Jan 28, 2013
Finance

Oleg's asymmetry

...postoperative ileus (POI) were $11M. Cubist gained the product through its December 2011 acquisition of Adolor Corp....
BioCentury | Jan 7, 2013
Clinical News

Entereg alvimopan regulatory update

...anastomosis in patients requiring surgery for colorectal disease. Cubist gained Entereg through its acquisition of Adolor Corp....
BioCentury | Nov 5, 2012
Clinical News

CB-5945: Phase III started

...slated to begin next half. Cubist gained the compound through its December 2011 acquisition of Adolor Corp....
BioCentury | Oct 22, 2012
Finance

Abbott's wild ride

...drug Entereg alvimopan were $10.1M. Cubist gained the product through its December 2011 acquisition of Adolor Corp....
BioCentury | Sep 5, 2012
Company News

Kalidex debuts

...Michael Dougherty, who joined Kalidex in May, was previously president and CEO at pain company Adolor Corp....
BioCentury | Jul 23, 2012
Finance

In like a lion . . .

...drug Entereg alvimopan were $9.7M. Cubist gained the product through its December 2011 acquisition of Adolor Corp....
Items per page:
1 - 10 of 436